{"id":"tak-755","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-755 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"TAK-755 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:27.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05714969","phase":"PHASE2","title":"A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-03-21","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":33},{"nctId":"NCT07392450","phase":"PHASE2","title":"A Study of TAK-755 in Adults With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-15","conditions":"Acute Ischemic Stroke","enrollment":222},{"nctId":"NCT03393975","phase":"PHASE3","title":"A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-10-13","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":52},{"nctId":"NCT06441578","phase":"","title":"A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-05-30","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":40},{"nctId":"NCT04683003","phase":"PHASE3","title":"A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura","status":"RECRUITING","sponsor":"Takeda","startDate":"2021-04-14","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":77},{"nctId":"NCT05770219","phase":"","title":"Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","status":"APPROVED_FOR_MARKETING","sponsor":"Takeda","startDate":"","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":""},{"nctId":"NCT03997760","phase":"PHASE1","title":"A Study of SHP655 (rADAMTS13) in Sickle Cell Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2019-10-21","conditions":"Sickle Cell Disease","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930","recombinant ADAMTS13","BAX 930","SHP655","rADAMTS13"],"phase":"phase_3","status":"active","brandName":"TAK-755","genericName":"TAK-755","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TAK-755 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}